Abbott Laboratories recently announced successful outcomes from its TRILUMINATE™ Pivotal trial for the TriClip™ system, showcasing significant improvements in patient outcomes for tricuspid regurgitation. This medical breakthrough, coupled with Abbott's consistent financial performance, including strong earnings for the fourth quarter of 2024 and strategic dividend announcements, aligns with a 17% rise in its stock price over the last quarter. Despite market turbulences and mixed market trends, with the Dow and S&P 500 showing a mixed performance and tariff anxieties weighing on sentiment, Abbott has maintained a positive trajectory.

Buy, Hold or Sell Abbott Laboratories? View our complete analysis and fair value estimate and you decide.

The end of cancer? These 21 emerging AI stocks are developing tech that will allow early idenification of life changing disesaes like cancer and Alzheimer's.

Abbott Laboratories has achieved a total return of 75.12% over the last five years, reflecting its resilience and strategic maneuvers in an evolving healthcare landscape. During this period, Abbott's focus on innovation with products such as leadless pacemakers and continuous glucose monitors has been instrumental. The strategic expansion in high-growth markets like Structural Heart and the robust execution of innovation in traditionally slower segments have contributed to this growth.

Recent initiatives, including a collaboration with Cadrenal Therapeutics for the TECH-LVAD trial and regulatory approval achievements, have strengthened Abbott's market position. Alongside product developments, the consistent dividend increases, exemplified by a 7.3% rise announced in December 2024, highlight Abbott's commitment to returning value to shareholders. In the past year alone, Abbott's earnings growth far exceeded the Medical Equipment industry, enhancing its appeal amidst broader market fluctuations.

Click here to discover the nuances of Abbott Laboratories with our detailed analytical financial health report.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.

Companies discussed in this article include NYSE:ABT.

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com